2550 Stock Overview
Changzhou Qianhong Biopharma CO.,LTD manufactures and distributes polysaccharide and protease drugs in China.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Changzhou Qianhong Biopharma CO.,LTD Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥5.73 |
| 52 Week High | CN¥6.34 |
| 52 Week Low | CN¥4.20 |
| Beta | 0.11 |
| 1 Month Change | 14.83% |
| 3 Month Change | 16.23% |
| 1 Year Change | 1.78% |
| 3 Year Change | 34.51% |
| 5 Year Change | 20.89% |
| Change since IPO | -28.46% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2550 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 7.3% | 3.1% | 0.9% |
| 1Y | 1.8% | -6.2% | -11.3% |
Return vs Industry: 002550 exceeded the CN Pharmaceuticals industry which returned -6.2% over the past year.
Return vs Market: 002550 exceeded the CN Market which returned -11.3% over the past year.
Price Volatility
| 2550 volatility | |
|---|---|
| 2550 Average Weekly Movement | 4.1% |
| Pharmaceuticals Industry Average Movement | 6.1% |
| Market Average Movement | 7.4% |
| 10% most volatile stocks in CN Market | 11.1% |
| 10% least volatile stocks in CN Market | 4.3% |
Stable Share Price: 002550 has not had significant price volatility in the past 3 months.
Volatility Over Time: 002550's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1971 | 1,102 | Ke Wang | www.qhsh.com.cn |
Changzhou Qianhong Biopharma CO.,LTD manufactures and distributes polysaccharide and protease drugs in China. The company offers its products in the form of tablets, hard capsules, lyophilized powder and lyophilized powder injections, small-volume injections, and raw materials. It provides enzymes, including pancreatic kininogenase series, asparaginase series, and compound digestive enzyme capsule II; and polysaccharides products, such as nadroparin calcium, enoxaparin sodium, dalteparin sodium, and asparaginase and heparin sodium.
Changzhou Qianhong Biopharma CO.,LTD Fundamentals Summary
| 2550 fundamental statistics | |
|---|---|
| Market cap | CN¥7.30b |
| Earnings (TTM) | CN¥181.86m |
| Revenue (TTM) | CN¥1.81b |
40.2x
P/E Ratio4.0x
P/S RatioIs 2550 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2550 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.81b |
| Cost of Revenue | CN¥1.05b |
| Gross Profit | CN¥768.81m |
| Other Expenses | CN¥586.94m |
| Earnings | CN¥181.86m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.14 |
| Gross Margin | 42.38% |
| Net Profit Margin | 10.02% |
| Debt/Equity Ratio | 2.3% |
How did 2550 perform over the long term?
See historical performance and comparison